Incretin-based therapies

Journal of Diabetes

Volumn 4, Issue 1, 2012, Pages 55-67

  Stonehouse, Anthony H ^a   Darsow, Tamara ^a   Maggs, David G ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Glucagon like peptide 1; Incretins; Pathophysiology; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; C PEPTIDE; CREATININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HORMONE RECEPTOR STIMULATING AGENT; INCRETIN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; NATRIURETIC PEPTIDE RECEPTOR B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ADD ON THERAPY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; APPETITE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG QUALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFLAMMATION; INSULIN RELEASE; LIVER; META ANALYSIS (TOPIC); NAUSEA; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREATITIS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SLEEP; STEVENS JOHNSON SYNDROME; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; RECEPTORS, GLUCAGON;

EID: 84857425029     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2011.00143.x     Document Type: Review

References (114)

1. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in T2D: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
2. Perley M, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects. J Clin Invest. 1967; 46: 1954-62.
3. Creutzfeldt W. The incretin concept today. Diabetologia. 1979; 16: 75-85.
4. Nauck MA, Wollschlager D, Werner J et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1[7-36 amide]) in patients with NIDDM. Diabetologia. 1996; 39: 1546-53.
5. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet. 1987; 2: 1300-4.
6. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004; 287: E199-206.
7. Vilsbøll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. 2004; 47: 357-66.
8. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of T2D. Diabetes. 2004; 53 (Suppl. 3): S190-6.
9. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001; 86: 3717-23.
10. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and β-cell function in T2D: A parallel-group study. Lancet. 2002; 359: 824-30.
11. Stein DT, Jayatillake H, Zheng BN et al. Type 2 diabetic subjects are highly responsive to GLP-1 induced insulin biosynthesis in vivo. Diabetes. 2010; 59 (Suppl. 1): 105-LB (Abstract).
12. Farilla L, Hui H, Bertolotto C et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002; 143: 4397-408.
13. Tourrel C, Bailbé D, Meile M-J, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001; 50: 1562-70.
14. Tourrel C, Bailbé D, Lacorne M, Meile M-J, Kergoat M, Portha B. Persistent improvement of T2D in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 2002; 51: 1443-52.
15. Zheng D, Ionut V, Mooradian V, Stefanovski D, Bergman RN. Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver. Diabetes. 2009; 58: 352-9.
16. Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004; 110: 955-61.
17. Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004; 109: 962-5.
18. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117: 2340-50.
19. Eng J, Kleinman WA, Singh L, Singh G, Raufman J-P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. 1992; 267: 7402-5.
20. Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with T2D mellitus. J Health Syst Pharm. 2005; 62: 173-81.
21. Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with T2D. J Clin Endocrinol Metab. 2005; 90: 5991-7.
22. Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with T2D. J Clin Endocrinol Metab. 2003; 88: 3082-9.
23. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. Curr Med Res Opin. 2008; 24: 2943-52.
24. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; For the exenatide 113 clinical study group. Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with T2D. Diabetes Care. 2004; 27: 2628-35.
25. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with T2D. Diabetes Care. 2005; 28: 1092-100.
26. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with T2D treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28: 1083-91.
27. Zinman B, Hoogwerf BJ, Durán García S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled Type 2 diabetes: A randomized trial. Ann Intern Med. 2007; 146: 477-85.
28. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with T2D treated for at least 3years. Curr Med Res Opin. 2008; 24: 275-86.
29. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA study group. Exenatide versus insulin glargine in patients with suboptimally controlled T2D: A randomized trial. Ann Intern Med. 2005; 143: 559-69.
30. Bunck MC, Diamant M, Cornér A et al. One-year treatment with exenatide improves β-cell function, compared to insulin glargine, in metformin treated T2D patients: A randomized, controlled trial. Diabetes Care. 2009; 32: 762-8.
31. Nauck MA, Duran S, Kim D et al. A comparison of twice daily exenatide and biphasic insulin aspart in patients with T2D who were suboptimally controlled with sulfonylurea and metformin: A non inferiority study. Diabetologia. 2007; 50: 259-67.
32. Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with T2D previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, 2-period, crossover non inferiority trial. Clin Ther. 2007; 29: 2333-48.
33. Kim D, MacConell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with T2D. Diabetes Care. 2007; 30: 1487-93.
34. Tracy MA, Ward KL, Firouzabadian L et al. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 1999; 20: 1057-62.
35. Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of T2D: A randomized, open-label, non-inferiority study. Lancet. 2008; 372: 1240-50.
36. Bergenstal RM, Wysham C, MacConell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of T2D (DURATION-2): A randomised trial. Lancet. 2010; 376: 431-9.
37. Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with T2D (DURATION-3): An open-label randomised trial. Lancet. 2010; 375: 2234-43.
38. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002; 45: 195-202.
39. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for T2D (LEAD-3 Mono): A randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373: 473-81.
40. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in T2D: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009; 32: 84-90.
41. Marre M, Shaw J, Brändle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulfonylurea over 26weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26: 268-78.
42. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with T2D mellitus (LEAD-4 Met+TZD). Diabetes Care. 2009; 32: 1224-30.
43. Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in T2D mellitus (LEAD-5 met+SU): A randomized controlled trial. Diabetologia. 2009; 52: 2046-55.
44. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for T2D: A 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374: 39-47.
45. Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment with the human once-weekly GLP-1 analogue taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with T2D mellitus inadequately controlled with metformin alone: A double-blind placebo-controlled study. Diabetes Care. 2009; 32: 1237-43.
46. Matthews JE, Stewart MW, De Boever EH et al.; Albiglutide Study Group. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with T2D. J Clin Endocrinol Metab. 2008; 93: 4810-7.
47. Bush MA, Matthews JE, De Boever EH et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009; 11: 498-505.
48. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in T2D: A randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009; 32: 1880-6.
49. Thorkildsen C, Neve S, Larsen BD, Meier E, Pedersen JS. GLP-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther. 2003; 307: 490-6.
50. Ratner RE, Rosenstock J, Boka G; On behalf of the DRI6012 study investigators. A dose-finding study of the new GLP-1 agonist AVE0010 in T2D insufficiently controlled with metformin. Diabetes. 2008; 58 (Suppl. 1): 433P (Abstract).
51. Christensen M, Knop FK, Holst JJ, Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of T2D mellitus. IDrugs. 2009; 12: 503-13.
52. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet. 2006; 368: 1696-705.
53. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with T2D. Diabetes Care. 2006; 29: 2632-7.
54. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with T2D mellitus. Diabetologia. 2006; 49: 2564-71.
55. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with T2D inadequately controlled with metformin alone. Diabetes Care. 2006; 29: 2638-43.
56. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with T2D: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006; 28: 1556-68.
57. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein PP; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with T2D mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007; 9: 733-45.
58. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with T2D inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007; 9: 194-205.
59. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group, Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with T2D. Diabetes Care. 2007; 30: 1979-87.
60. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naïve patients with T2D. Curr Med Res Opin. 2009; 25: 2401-11.
61. DeFronzo RA, Hissa MN, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled T2D with metformin alone. Diabetes Care. 2009; 32: 1649-55.
62. Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with T2D and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009; 94: 4810-9.
63. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug naïve-patients with T2D. Diabetes Res Clin Pract. 2007; 76: 132-8.
64. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24weeks in patients with T2D inadequately controlled with metformin. Diabetes Care. 2007; 30: 890-5.
65. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: A 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008; 10: 82-90.
66. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with T2D: A 24-week, double-blind, randomized trial. Diabetes Care. 2007; 30: 217-23.
67. Holcombe JH, Shenouda SK, Heilmann CR. Exenatide resulted in significantly greater improvements in 24h average glucose compared to sitagliptin in patients with T2D. Diabetes. 2010; 59 (Suppl. 1): 674P (Abstract).
68. Pratley RE, Nauck N, Bailey T et al. Liraglutide versus sitagliptin for patients with T2D who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet. 2010; 375: 1447-56.
69. Noel RA, Braun DK, Patterson RE, Bloomgren G. Increased risk of acute pancreatitis and biliary disease observed in patients with T2D: A retrospective, cohort study. Diabetes Care. 2009; 32: 834-8.
70. Bloomgren G, Dore D, Patterson R, Noel R, Braun D, Seeger J. Incidence of acute pancreatitis in exenatide initiators compared to other antidiabetic drug initiators: A retrospective, cohort study. Diabetes. 2009; 58 (Suppl. 1): 158OR (Abstract).
71. Herrera V, Aubert R, Tully L et al. Pancreatitis in patients treated with exenatide or sitagliptin. Diabetes. 2009; 58 (Suppl. 1): 10LB (Abstract).
72. Liraglutide Prescribing Information. Available from: (accessed 20 October 2010).
73. Bjerre Knudsen L, Madsen LW, Andersen S et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010; 151: 1473-86.
74. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting. J Nucl Med. 2007; 48: 736-43.
75. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide: The FDA's review of a new antidiabetic therapy. N Engl J Med. 2010; 362: 774-7.
76. Sitagliptin Prescribing Information. Available from: (accessed 20 October 2010).
77. McIntosh CHS, Demuth HU, Kim SJ, Pospisilik JA, Pederson RA. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Int J Biochem Cell Biol. 2006; 38: 860-72.
78. Bunck MC, Cornér A, Eliasson B et al. Three-year exenatide therapy, followed by a 4-week off-drug period, had a sustainable effect on β-cell disposition index in metformin treated patients with T2D. Diabetes. 2009; 58 (Suppl. 1): 0728P (Abstract).
79. Bergenstal R, Kim T, Yan P et al. Exenatide once weekly improved cardiometabolic risk factors in subjects with T2D during one year of treatment. Diabetes. 2009; 58 (Suppl. 1): 165OR (Abstract).
80. Horton E, Walsh B, Han J et al. Treatment with once-weekly exenatide for 52weeks resulted in improvements in glycemic control, body weight, and markers of cardiovascular risk and hepatic injury. Diabetes. 2010; 59 (Suppl. 1): 0582P (Abstract).
81. Kim T, Taylor K, Wilhelm K, Trautmann M, Zhuang D, Porter L. Exenatide once weekly treatment elicits sustained glycemic control and weight loss over 2years. Diabetes. 2009; 58 (Suppl. 1): 159OR. (Abstract).
82. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with T2D. Am J Hypertens. 2010; 23: 334-9.
83. Fonseca V, Madsbad S, Falahati A, Zychma MJ, Plutzky J. Once-daily human GLP-1 analog liraglutide reduces systolic BP: A meta-analysis of 6 clinical trials. Diabetes. 2009; 58 (Suppl. 1): 545P (Abstract).
84. Shen L, Han J, Yushmanova I, Bruce S, Porter L. Cardiovascular safety of exenatide BID: An integrated analysis from long-term controlled clinical trials in subjects with T2D. Diabetes. 2009; 58 (Suppl. 1): 366OR (Abstract).
85. Bruce KD, Byrne CD. The metabolic syndrome: Common origins of a multifactorial disorder. Postgrad Med J. 2009; 85: 614-21.
86. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int. 2006; 26: 1015-7.
87. Gupta NA, Mells J, Dunham RM. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010; 51: 1584-92.
88. Timmers L, Henriques JPS, de Kleijn DPV et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009; 53: 501-10.
89. Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept. 2008; 146: 243-9.
90. Kristensen J, Mortensen UM, Schmidt M, Nielsen PH, Nielsen TT, Maeng M. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord. 2009; 9: 31.
91. Noyan-Ashraf MH, Momen MA, Ban K et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009; 58: 975-83.
92. Kendall D, Bhole D, Guan X et al. Exenatide treatment for 82weeks reduced C-reactive protein, HbA1c, and body weight in patients with T2D mellitus. Diabetologia. 2006; 49 (Suppl. 1): S475 (Abstract).
93. Bunck MC, Diamant M, Eliasson B et al. Beneficial changes on body composition and circulating adiponectin and hsCRP levels following one year of exenatide therapy, compared with insulin glargine, in metformin-treated patients with T2D. Diabetes. 2009; 58 (Suppl. 1): 469P (Abstract).
94. Bunck MC, Cornér A, Eliasson B et al. One year exenatide therapy, compared with insulin glargine, reduces postprandial oxidative stress in metformin-treated patients with T2D. Diabetes. 2009; 58 (Suppl. 1): 548P (Abstract).
95. Derosa G, Maffioli P, Salvadeo SA et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther. 2010; 12: 233-40.
96. Frederich R, Alexander JH, Fiedorek FT et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for T2D. Postgrad Med. 2010; 122: 16-27.
97. Marcheva B, Bass J, Rmasey K et al. Impact of circadian gene transcription factors in pancreatic β cell function and diabetes. Diabetes. 2008; 57 (Suppl. 1): 1664P (Abstract).
98. Varanasi A, Chaudhuri A, Dhindsa S et al. Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations. Endocr Pract. 2011; 17: 192-200.
99. Wu JD, Xu XH, Zhu J et al. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011; 13: 143-8.
100. Perry T, Holloway HW, Weerasuriya A et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol. 2007; 203: 293-301.
101. Perry T, Lahiri DK, Chen D et al. A novel neurotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002; 300: 958-66.
102. Biswas SC, Buteau J, Greene LA. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem Res. 2008; 33: 1845-51.
103. Barone MT, Menna-Barreto L. Diabetes and sleep: A complex cause-and-effect relationship. Diabetes Res Clin Pract. 2011; 91: 129-37.
104. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: A novel risk factor for insulin resistance and T2D. J Appl Physiol. 2005; 99: 2008-19.
105. Mallon L, Broman JE, Hetta J. High incidence of diabetes in men with sleep complaints or short sleep duration: A 12-year follow-up study of a middle-aged population. Diabetes Care. 2005; 28: 2762-7.
106. Abbas T, Faivre E, Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res. 2009; 205: 265-71.
107. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther. 2002; 302: 881-8.
108. Perry T, Lahiri DK, Sambamurti K et al. Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J Neurosci Res. 2003; 72: 603-12.
109. Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol. 2009; 202: 431-9.
110. Näslund E, Barkeling B, King N et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord. 1999; 23: 304-11.
111. Gutzwiller JP, Drewe J, Göke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999; 276: R1541-4.
112. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999; 20: 876-913.
113. Zhou J, Wang X, Pineyro MA, Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes. 1999; 48: 2358-66.
114. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000; 141: 4600-5.